BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li ZB, Li L, Niu XX, Chen SH, Fu YM, Wang CY, Liu Y, Shao Q, Chen G, Ji D. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int. 2021;41:1254-1264. [PMID: 33404182 DOI: 10.1111/liv.14786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Uchida Y, Nakao M, Yamada S, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PLoS One 2022;17:e0262764. [PMID: 35180213 DOI: 10.1371/journal.pone.0262764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022. [PMID: 35178711 DOI: 10.1111/apt.16788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Q, Cai DC, Hu P, Ren H. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl) 2021;134:2810-7. [PMID: 34759219 DOI: 10.1097/CM9.0000000000001793] [Reference Citation Analysis]
4 Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10295-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study. Aliment Pharmacol Ther 2022. [PMID: 35735794 DOI: 10.1111/apt.17107] [Reference Citation Analysis]
6 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, Peng L, Xie C. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antiviral Therapy 2022;27:135965352210823. [DOI: 10.1177/13596535221082399] [Reference Citation Analysis]
8 Li ZB, Chen DD, He QJ, Li L, Zhou G, Fu YM, Deng Y, Niu XX, Chu F, Gao XP, Zou Z, Chen G, Ji D. The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study. Front Pharmacol 2021;12:734090. [PMID: 34483945 DOI: 10.3389/fphar.2021.734090] [Reference Citation Analysis]
9 Ji D, Chen Y, Shang Q, Liu H, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Hu X, Wang X, Chen D, Li Z, Dong Z, Chen G, Yang Y. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. Am J Gastroenterol 2021. [PMID: 33840727 DOI: 10.14309/ajg.0000000000001239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen YC, Hsu CW, Chien RN, Tai DI. One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study. Medicine (Baltimore) 2022;101:e29269. [PMID: 35758355 DOI: 10.1097/MD.0000000000029269] [Reference Citation Analysis]